L. Wright

发表

Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β-hydroxylase inhibitor.

P. Soares-da-Silva, B. Igreja, L. Wright, 2016, Journal of the American Society of Hypertension : JASH.

Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat

P. Soares-da-Silva, M. Bonifácio, B. Igreja, 2014, Hypertension Research.

Cardiometabolic and Inflammatory Benefits of Sympathetic Down-Regulation with Zamicastat in Aged Spontaneously Hypertensive Rats.

P. Soares-da-Silva, B. Igreja, L. Wright, 2019, ACS pharmacology & translational science.

Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat

P. Soares-da-Silva, M. Bonifácio, B. Igreja, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in rat.

P. Soares-da-Silva, M. Bonifácio, B. Igreja, 2014, European journal of pharmacology.

Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-β-Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2010, Drugs in R&D.

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers.

A. Falcão, P. Soares-da-Silva, J. Rocha, 2009, Molecular nutrition & food research.

Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations

A. Falcão, P. Soares-da-Silva, J. Rocha, 2014, European Journal of Clinical Pharmacology.

Pharmacokinetic–Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa

A. Falcão, P. Soares-da-Silva, J. Maia, 2004, Clinical neuropharmacology.

Pharmacokinetic–pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide

A. Falcão, P. Soares-da-Silva, J. Maia, 2003, European Journal of Clinical Pharmacology.

Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

A. Falcão, P. Soares-da-Silva, M. Bonifácio, 2013, British journal of clinical pharmacology.

Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects

A. Falcão, P. Soares-da-Silva, M. Bonifácio, 2013, Clinical Pharmacokinetics.

Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200 mg/50 mg

A. Falcão, P. Soares-da-Silva, J. Rocha, 2008, Drugs in R&D.

Induction of Phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in Human Peripheral Blood T-lymphocytes by 8-Bromo-cAMP and Gs-coupled Receptor Agonists

I. Adcock, N. Suttorp, R. Newton, 1998, The Journal of Biological Chemistry.

Pharmacological profile of opicapone, a third‐generation nitrocatechol catechol‐O‐methyl transferase inhibitor, in the rat

P. Soares-da-Silva, M. Bonifácio, L. Torrão, 2015, British journal of pharmacology.

Pharmacological Profile of Opicapone in Wistar rat

P. Soares-da-Silva, M. Bonifácio, L. Torrão, 2014 .

2.243 OPICAPONE: CHARACTERIZATION OF A NOVEL PERIPHERAL LONG-ACTING CATECHOL-O-METHYLTRANSFERASE INHIBITOR

P. Soares-da-Silva, M. Bonifácio, L. Torrão, 2012 .

Single‐Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5–453), a New Dopamine β‐Hydroxylase Inhibitor, in Healthy Subjects

A. Falcão, P. Soares-da-Silva, M. Bonifácio, 2012, Journal of clinical pharmacology.

Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations

A. Falcão, P. Soares-da-Silva, J. Rocha, 2014, European Journal of Clinical Pharmacology.

Development and validation of an enantioselective liquid-chromatography/tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma.

P. Soares-da-Silva, L. Wright, A. Loureiro, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Effect of food on the pharmacokinetic profile of trans-resveratrol.

A. Falcão, P. Soares-da-Silva, J. Rocha, 2008, International journal of clinical pharmacology and therapeutics.

Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone.

P. Soares-da-Silva, M. Pinho, M. Bonifácio, 2009, Biochemical pharmacology.

Pharmacokinetics of Trans‐resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2009, Journal of clinical pharmacology.

Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat

P. Soares-da-Silva, M. Serrão, E. Moura, 2015, Hypertension Research.

Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor.

P. Soares-da-Silva, M. Bonifácio, D. Learmonth, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action

P. Soares-da-Silva, M. Bonifácio, L. Wright, 2015, Pharmacology research & perspectives.

N-Acetylation of Etamicastat, a Reversible Dopamine-β-Hydroxylase Inhibitor

P. Soares-da-Silva, M. Bonifácio, L. Wright, 2013, Drug Metabolism And Disposition.

Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat.

P. Soares-da-Silva, M. Bonifácio, B. Igreja, 2015, European journal of pharmacology.

Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease

C. Sampaio, J. Ferreira, M. Coelho, 2008, Clinical neuropharmacology.

Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus

P. Soares-da-Silva, G. Sierra-Paredes, G. Sierra-marcuňo, 2014, BMC Neuroscience.

Hepatic UDP-Glucuronosyltransferase Is Responsible for Eslicarbazepine Glucuronidation

P. Soares-da-Silva, M. Bonifácio, L. Wright, 2011, Drug Metabolism and Disposition.

Effects of zamicastat treatment in a genetic model of salt‐sensitive hypertension and heart failure

P. Soares-da-Silva, B. Igreja, L. Wright, 2019, European journal of pharmacology.

Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor

A. Falcão, P. Soares-da-Silva, J. Maia, 2010, Current medical research and opinion.

Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation

P. Soares-da-Silva, M. Bonifácio, L. Almeida, 2006, Drug Metabolism and Disposition.

Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor

P. Soares-da-Silva, M. Bonifácio, L. Torrão, 2014, Neuropharmacology.

Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.

A. Falcão, P. Soares-da-Silva, J. Rocha, 2009, Clinical Therapeutics.

Phosphodiesterase expression in human epithelial cells.

I. Adcock, J. Seybold, A. Robichaud, 1998, The American journal of physiology.

Phosphodiesterase expression in human epithelial cells.

J. Seybold, A. Robichaud, L. Wright, 1998, American journal of physiology. Lung cellular and molecular physiology.

Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in rat.

P. Soares-da-Silva, M. Bonifácio, L. Wright, 2014, European journal of pharmacology.